HOTHHoth Therapeutics

About Hoth Therapeutics
Hoth Therapeutics (NASDAQ:HOTH) is a biopharmaceutical company focused on developing innovative therapies for patients battling conditions ranging from dermatological disorders to chronic diseases. Dedicated to improving patient care, Hoth Therapeutics invests in research and development to bring novel treatments from the laboratory to the clinic. Their projects include potential therapies for acne, eczema, chronic wound disorders, and more, aiming to address unmet medical needs in these areas. Operating with a mission to enhance patient quality of life through groundbreaking medical solutions, Hoth Therapeutics continues to push the boundaries of science to offer hope and advance healthcare outcomes.
What is HOTH known for?
Snapshot
Public US
Ownership
2017
Year founded
2
Employees
New York, United States
Head office
1 of 2
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
New York City, US
Produtos e/ou serviços de Hoth Therapeutics
- BioLexa Platform, a proprietary antimicrobial therapy for the treatment of eczema.
- HT-001, a topical treatment designed for the alleviation of rash and skin disorders associated with initial and repeat courses of epidermal growth factor receptor (EGFR) inhibitor therapy.
- VNLG-152, novel retinamides (retinoic acid metabolism blocking agents) for the treatment of dermatological diseases.
- HT-003, a novel therapeutic for the treatment of acne vulgaris.
- A COVID-19 therapeutic, focusing on the prevention of viral entry and replication.
- Gene therapy for patients suffering from Cutaneous Squamous Cell Carcinoma (CSCC).
equipe executiva do Hoth Therapeutics
- Mr. Robb KnieFounder, President, CEO & Chairman
- Mr. David S. BrionesChief Financial Officer
- Ms. Hayley SpringerExecutive Vice President of Operations